Using ultrasound to improve detection of non-alcoholic fatty liver disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to enhance the detection of non-alcoholic fatty liver disease (NAFLD) using an algorithm called COSIE, which improves the accuracy of ultrasound measurements of liver tissue. The study will involve healthy volunteers and patients undergoing liver MRI, focusing on the backscatter coefficient (BSC) to identify steatosis. By refining the measurement process, the study seeks to enable earlier and more reliable detection of NAFLD, which is increasingly prevalent due to common cancer therapies. The approach leverages existing ultrasound technology, making it a cost-effective screening tool.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Healthy Volunteers:

* Healthy male or female adults (18 or above).
* Volunteers must consider themselves fit and healthy.
* RMH and/or ICR employees.

Patients:

* Patients undergoing liver MRI as part of clinical standard of care with evidence of steatosis on preceding MRI.
* Aged 18 and above.

Exclusion Criteria:

Healthy Volunteers:

* Volunteers that are under investigation or planning to consult their GP to seek investigation for an undiagnosed condition, particularly regarding pelvic or abdominal disease or injury.
* Healthy volunteers who do not have an NHS number or who are not registered with a GP will be excluded.

Patients:

• Severe liver fibrosis (fibrosis stage F4) or severe cirrhosis.

Where it's running

• The Royal Marsden Hospital
  London, Greater London, United Kingdom Recruiting

Study contacts

• Study coordinator: Emma J Harris, PhD
• Email: emma.harris@icr.ac.uk
• Phone: +442087224576

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Hydroxychloroquine treatment for nonalcoholic steatohepatitis

  This study will test whether taking hydroxychloroquine daily for 12 months helps adults with nonalcoholic steatohepatitis and is safe.

  Recruiting Phase 3 National Taiwan University Hospital · Taipei, Taiwan · NCT07265297

• Multiple under-the-skin injections of B1344 for adults with NAFLD and NASH

  This trial will test whether repeated subcutaneous injections of an experimental drug called B1344 are safe and affect liver fat and related measures in adults with NAFLD or NASH.

  Recruiting Phase 1 Tasly Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality and 4 other locations · NCT07128797

• Evaluating efruxifermin for patients with compensated cirrhosis due to NASH/MASH

  This study is testing a new medication called efruxifermin to see if it can improve liver health in people with compensated cirrhosis caused by NASH or MASH.

  Recruiting at 322 sites Phase 3 Akero Therapeutics, Inc · Birmingham, Alabama and 344 other locations · NCT06528314

• A registry for studying Non-Alcoholic Fatty Liver Disease in Europe

  This study is collecting health information and samples from people with Non-Alcoholic Fatty Liver Disease to learn more about the disease and find better ways to track its progress.

  Recruiting at 33 sites Newcastle University · Antwerp and 36 other locations · NCT04442334

• Observational cohort for non-alcoholic fatty liver disease and related conditions

  This study is trying to learn more about non-alcoholic fatty liver disease and its related conditions by looking at patients with different stages of the disease and comparing them to people with diabetes and obesity who don't have it.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma, Rome/lazio/italy · NCT04371042

• Understanding the connection between obesity and liver inflammation

  This study looks at how extra fat around the liver and inflammation in body fat affect liver health and insulin resistance in people with obesity, especially those having gastric bypass surgery.

  Recruiting Mayo Clinic · Scottsdale, Arizona · NCT04232566

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.